NASDAQ · CDNA
Healthcare · Medical - Diagnostics & Research
$47.50
Up+$2.53 (+5.33%)
Updated Aug 25, 2026, 4:40 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CDNA closed at $47.50 after 21 trading sessions, up 30.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $48.30 | $48.51 | $46.92 | $47.50 | 769.59K |
| Aug 21, 2026 | $46.99 | $48.72 | $46.0497 | $48.61 | 1.16M |
| Aug 20, 2026 | $45.902 | $47.845 | $45.332 | $46.99 | 911.18K |
| Aug 19, 2026 | $46.85 | $48.4299 | $46.41 | $46.51 | 1.89M |
| Aug 18, 2026 | $45.68 | $46.5174 | $44.80 | $46.18 | 840.13K |
| Aug 17, 2026 | $45.325 | $47.075 | $45.02 | $46.38 | 733.14K |
| Aug 14, 2026 | $47.035 | $47.3425 | $45.25 | $45.32 | 708.98K |
| Aug 13, 2026 | $47.53 | $47.95 | $46.51 | $47.38 | 739.27K |
| Aug 12, 2026 | $47.47 | $47.55 | $46.5401 | $47.31 | 984.93K |
| Aug 11, 2026 | $47.07 | $47.94 | $46.2606 | $47.23 | 638.63K |
| Aug 10, 2026 | $46.58 | $48.2936 | $46.088 | $47.07 | 1.23M |
| Aug 7, 2026 | $44.88 | $46.74 | $44.57 | $46.69 | 966.83K |
| Aug 6, 2026 | $46.00 | $46.00 | $44.58 | $44.81 | 790.07K |
| Aug 5, 2026 | $47.00 | $47.08 | $45.39 | $45.50 | 1.12M |
| Aug 4, 2026 | $47.00 | $48.00 | $46.24 | $47.09 | 1.65M |
| Aug 3, 2026 | $47.218 | $49.76 | $44.5418 | $47.85 | 2.93M |
| Jul 31, 2026 | $42.49 | $45.00 | $40.67 | $43.71 | 2.78M |
| Jul 30, 2026 | $35.18 | $38.33 | $35.01 | $38.10 | 1.74M |
| Jul 29, 2026 | $35.77 | $36.54 | $35.29 | $35.41 | 744.48K |
| Jul 28, 2026 | $36.29 | $37.09 | $35.11 | $35.75 | 939.4K |
| Jul 27, 2026 | $37.21 | $37.74 | $36.25 | $36.36 | 604.62K |
The latest Smart Investors Daily articles mentioning CDNA.
CDNA research
Company profile and research snapshot.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| Jul 16, 2026 | BTIG | Buy | — |
| Apr 29, 2026 | BTIG | Buy | — |
| Feb 26, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
ChartMill · Aug 6, 2026
CareDx stock aligns with Navellier's growth rules: accelerating earnings, rising estimates, margin expansion, high ROE. A momentum-oriented pick worth review.
Benzinga · Aug 6, 2026
BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $45 to $60.
Benzinga · Jul 31, 2026
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral and maintains $46 price target.
SeekingAlpha · Jul 30, 2026
CareDx, Inc. (CDNA) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsNina DekaJohn Hanna - President, CEO & DirectorKeith Kennedy -...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CDNA.
